Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Ángel Crespo López(Hospital Universitario Infanta Cristina), Robert F. Grover(University of Colorado Boulder), Jan Bakker(Pontificia Universidad Católica de Chile), Michael Brockway(St. Johns Hospital), Steven H. Grossman(GlaxoSmithKline (Netherlands)), Jill Donaldson(GlaxoSmithKline (Netherlands)), José A. Lorente(Universidad de Granada), Jukka Takala(University of Bern), Antonio Anzueto, Sheila M. Willatts(Erasmus Hospital), Carl Arneson(GlaxoSmithKline (Netherlands)), Angela McLuckie(Guy's Hospital), Laurent Holzapfel(Servier (France)), G.Richard Grove(GlaxoSmithKline (Netherlands)), Michael Silverman(Lakeridge Health), Desmond P. Breen(Royal Hallamshire Hospital), Jay S. Steingrub(Response Biomedical (Canada))
Critical Care Medicine
January 1, 2004
Cited by 921


Related Papers